Safety of INP104 in Migraine Patients With Cardiovascular Risk Factors: Post Hoc Subgroup Analysis of the Phase 3 STOP 301 Study

Presented at the AHS 65th Annual Scientific Meeting, June 15-18, 2023, Austin, Texas Authors: Dafer R, Tietjen G, Rothrock J, Hirman J, Vann R, Gutierrez J, Ray S, Shrewsbury S, Aurora S One sentence summary: This post hoc subgroup analysis of the Phase 3 STOP 301 study evaluated the safety of INP104 (dihydroergotamine mesylate and the […] The post Safety of INP104 in Migraine Patients With Cardiovascular Risk Factors: Post Hoc Subgroup Analysis of the Phase 3 STOP 301 Study appeared first on Impel Pharmaceuticals .